Viela Bio officially goes public - Washington Business Journal
Viela Bio Enters Strategic Collaboration with Hansoh Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases and Hematologic Cancers in China | Business Wire
Viela Bio Company Profile: Acquisition & Investors | PitchBook
Hedge Funds Cautiously Watching Viela Bio, Inc. (VIE)
Viela Bio Begins U.S. IPO Effort (NASDAQ:VIE) | Seeking Alpha
Viela Bio, Inc. Rings the Opening Bell in Celebration of its IPO | Nasdaq
VIELABIO - Viela Bio, Inc. Trademark Registration
Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio | Business Wire
Why Viela Bio Stock Is Skyrocketing Today | The Motley Fool
PANTHERx® Chosen as Exclusive Rare Pharmacy Partner by Viela Bio, Inc. for Uplizna™ (inebilizumab-cdon) for Adult Patients with AQP4+ Neuromyelitis Optica Spectrum Disorder (NMOSD) - PANTHERx Rare
PANTHERx® Chosen as Exclusive Rare Pharmacy Partner by Viela Bio, Inc. for Uplizna™ (inebilizumab-cdon) for Adult Patients with AQP4+ Neuromyelitis Optica Spectrum Disorder (NMOSD)
Horizon Makes The Case For An Ambitious $10Bn Sales Goal :: Scrip
Viela Bio, Inc. - Tender Offer Option Symbol: VIE
Tim Walbert on Twitter: "A special moment in Times Square today! Thank you @Nasdaq for featuring @HorizonNews' acquisition of Viela Bio. $HZNP https://t.co/9ItDBLpElL" / Twitter
Viela Bio Inc (VIE) Investor Presentation - Slideshow (NASDAQ:VIE) | Seeking Alpha
Viela Bio | LinkedIn
VIE Stock Price, Viela Bio, Inc. Stock Quote (NASDAQ) | CoinCodex
Viela Bio, Inc. - 10/2/2019 | Cowen
UPLIZNA - Viela Bio, Inc. Trademark Registration
Viela Bio Spins Out of AstraZeneca's MedImmune with $250 Million Series A Funding | BioSpace
IPO Roundup: Viela Bio Inc, Frequency Therapeutics Inc, MetroCity Bankshares Inc, ADC Therapeutics SA, Monopar Therapeutics Inc
Viela Bio | LinkedIn
Viela Bio Closes $75 Million Series B Financing | Business Wire
Viela Bio Enters Strategic Collaboration with Hansoh Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases and Hematologic Cancers in China - NAI 500
Viela Bio, Inc.
Horizon Therapeutics to acquire Viela Bio for $3bn
VIELA BIO, INC.: VIE Azione Prezzo| US9266131005 | MarketScreener
